ABL announces the hire of Jarlath Keating as Chief Commercial Officer (CCO). As CCO, Keating will report to the Chief Executive Officer (CEO) and will head global Commercial Operations for ABL.
Most recently, Keating served as the Vice President of Global Commercial Operations for MilliporeSigma's Process Solutions Services division, leading the BioReliance biological safety testing and biomanufacturing services. Previously, Keating served in commercial roles of increasing levels of responsibility including Vice President of Global Sales, Senior Sales Director for North America and Director of Sales for Europe and Asia Pacific for the BioReliance organization, as well as business development and technical roles at HyClone Laboratories, Life Technologies and Lonza Biologics.
Keating graduated from the University of Teesside in the United Kingdom with a Bachelor's of Science degree in Process Biotechnology.
"It is a pleasure to join the ABL team as the Chief Commercial Officer," said Keating. "I will be working closely with the global business development and marketing groups to establish a cross-functional and integrated commercial strategy. Our focus will be on delivering best-in-class service to our rapidly expanding global client base."
"Jarlath's experience in leading commercial operations will enable ABL to formulate and execute a robust commercial strategy to expand our global business and create substantial value for our customers. Also, with the recent hire of Marykay Marchigiani as Chief Financial Officer, we continue to strengthen the executive leadership at ABL, ensuring we are well positioned for future growth," Dr. Thomas VanCott, President and CEO of ABL, said.